Systems and Methods for Prostate Treatment
First Claim
Patent Images
1. A method for treating BPH, comprising:
- delivering a thermal energy to a targeted prostate tissue to cause protein denaturation in the targeted prostate tissue; and
implanting a stent in a prostatic urethra to apply tissue-compressing forces to the targeted prostate tissue, allowing for protein renaturation and tissue remodeling under said tissue-compressing forces.
1 Assignment
0 Petitions
Accused Products
Abstract
An energy delivery probe is provided that may include any of a number of features. One feature of the energy delivery probe is that it can apply energy to tissue, such as a prostrate, to shrink, damage, denaturate the prostate. In some embodiments, the energy can be applied with a vapor media. Another feature of the energy delivery probe is that it can deploy a stent to apply tissue-compressive forces to the prostate tissue after energy delivery. Methods associated with use of the energy delivery probe are also covered.
-
Citations
15 Claims
-
1. A method for treating BPH, comprising:
-
delivering a thermal energy to a targeted prostate tissue to cause protein denaturation in the targeted prostate tissue; and implanting a stent in a prostatic urethra to apply tissue-compressing forces to the targeted prostate tissue, allowing for protein renaturation and tissue remodeling under said tissue-compressing forces. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A method for treating BPH, comprising:
-
delivering a thermal energy to a transition zone prostate tissue to ablate the transition zone prostate tissue; and deploying a stent in a prostatic urethra that applies tissue-compressing forces to the transition zone prostate tissue during healing of the transition zone prostate tissue. - View Dependent Claims (8)
-
-
9. A system for treating a prostate disorder, comprising:
-
an introducer sized and configured to be inserted into a urethra and to access a prostatic urethra of a patient; and a stent of a hydrolytically unstable material sized and configured to be deployed in the prostatic urethra from the introducer. - View Dependent Claims (10, 11, 12, 13, 14, 15)
-
Specification